TrialReader


Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease

NCT03456934 — Not applicable, Completed, 249 participants, Société des Produits Nestlé (SPN)

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease: A Multi-centred, Randomised, Controlled Trial

RegistryNCT03456934, acronym BabyGrowth
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: quadruple, other
Enrollment249 (Actual)
SponsorSociété des Produits Nestlé (SPN) (Industry); collaborators: University College, London
ConditionsInfant Formula, Growth
InterventionsModified infant formula, Standard infant formula (Other)
Datesstart 2017-08-07, primary completion 2021-09-30, completion 2022-10-13, first posted 2018-03-07, last updated 2023-03-17
Locations1 site in United Kingdom

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Infant Formula All trials for Growth All trials of Modified infant formula All trials of Standard infant formula

-Summary

The primary objective of this study is to investigate if consumption of lower protein formula can slow the rate of weight gain of formula-fed infants between 3 and 12 months of age. Secondary objectives include investigation into whether infant nutrition and growth have an impact on later risk of obesity and cardiovascular disease.

Expand all sections  ·  Collapse all

+Detailed description

Obesity and its cardiovascular consequences are the most important causes of morbidity and mortality worldwide. Breastfed infants have been shown to have less cardiovascular risk factors in adulthood, which can be partially explained by their slower growth compared to formula fed infants. The primary objective of this study is to investigate if consumption of lower protein formula can slow the rate of weight gain of formula-fed infants between 3 and 12 months of age. Secondary objectives include investigation into whether infant nutrition and growth have an impact on later risk of obesity and atherosclerotic cardiovascular disease (CVD), the critical windows for these programming effects, and the mechanisms of action.

+Arms and interventions

ArmTypeInterventionsDescription
Experimental GroupExperimentalOther: Modified infant formulaModified infant formula given from 3 to 12 months of age, as per standard requirement.
Control GroupActive comparatorOther: Standard infant formulaStandard infant formula given from 3 to 12 months of age, as per standard requirement.
Breast-fed Reference GroupNo interventionNon-randomized infants who are predominantly breast-fed at time of enrollment.
  • Modified infant formula (Other): Test formula with lower protein content than standard formula
  • Standard infant formula (Other): Standard infant formula

+Outcome measures

Primary outcomes

  • Infant weight gain [Between ages 14 weeks (+/- 1 week) and 12 months (+/- 2 weeks)]: Rate of weight gain (g/d)

Secondary outcomes

  • Body mass index (BMI)-for-age Z-score [Age 2 years (+/- 1 month)]: Based on World Health Organization (WHO) growth standards
  • Height-for-age Z-score [Age 2 years (+/- 1 month)]: Based on WHO growth standards
  • Adiposity [Age 2 years (+/- 1 month)]: Sum of 4 skinfolds (triceps, biceps, sub-scapular, supra-iliac)
  • Fat mass [Age 2 years (+/- 1 month)]: Deuterium dilution (assessed in subset)

Other outcomes

  • Infant weight gain [Between 6 and 12 months]: Rate of weight gain (g/d)
  • Weight [Ages 4, 5, 6, 12 and 24 months]: Body weight (kg)
  • Length or height [Ages 4, 5, 6, 12 and 24 months]: Length or height (cm)
  • Head circumference [Ages 4, 5, 6, 12 and 24 months]: Head circumference (cm)
  • Body mass index [Ages 6, 12 and 24 months]: Weight and length or height will be combined to report BMI in kg/m\^2
  • Weight-for-age Z-score [Ages 14 weeks and 4, 5, 6, 12 and 24 months]: Based on WHO growth standards
  • Weight-for-length Z-score [Ages 14 weeks and 4, 5, 6, 12 and 24 months]: Based on WHO growth standards
  • Height-for-age Z-score [Ages 14 weeks and 4, 5, 6, and 12 months]: Based on WHO growth standards
  • BMI-for-age Z-score [Ages 14 weeks and 4, 5, 6, and 12 months]: Based on WHO growth standards
  • Adverse events [Ages 14 weeks and 4, 5, 6, 9, 12 and 24 months]: Safety
  • Feeding intake [Ages 14 weeks and 4, 5, 6, and 12 months]: Infant feeding questionnaire
  • Feeding tolerance [Ages 14 weeks and 4, 5, 6, and 12 months]: GI symptom and stool pattern questionnaire
  • Metabolic markers of cardiovascular health [Ages 6 and 12 months]: Blood sample (in a subset)
  • Blood pressure [At age 12 and 24 months]: Systolic and diastolic blood pressure (in a subset)
  • Appetite and feeding / eating behavior [Ages 14 weeks and 4, 5, 6, and 24 months]: Baby and Children's Eating Behavior Questionnaire

+Eligibility

Sex: All, ages: 13 Weeks to 15 Weeks, accepts healthy volunteers

Inclusion Criteria:

* Healthy term infant
* Infant is aged 14 weeks (+/- 1 week)
* Infant is exclusively formula feeding or predominantly breast-feeding at age 14 weeks

Exclusion Criteria:

* Any adverse maternal, fetal or infant medical history that may have effects on growth and/or development
* Infant born with congenital disease or malformation affecting growth and/or development
* Food allergy to any trial products (e.g. milk, soy)

+Locations (1)

FacilityCityCountryStatus
UCL Institute of Child HealthLondonUnited Kingdom

+Publications

  • Results publication: Gonzalez-Garay AG, Serralde-Zuniga AE, Medina Vera I, Velasco Hidalgo L, Alonso Ocana MV. Higher versus lower protein intake in formula-fed term infants. Cochrane Database Syst Rev. 2023 Nov 6;11(11):CD013758. doi: 10.1002/14651858.CD013758.pub2. PMID 37929831

+Investigators

  • Atul Singhal, MD, Principal investigator, Childhood Nutrition Research Centre, University College London, Institute of Child Health

My Notes